Drugs / SLV-324
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07108114 | Aug 2025 → May 2027 expected | metastatic neoplasm | Solve Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLV-324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07108114 ↗ |
| Route | Intravenous | “SLV-324 will be administered intravenously (IV) in repeated cycles” NCT07108114 ↗ |